Maytansinoids

Maytansinoids are potent microtubule-targeted compounds that inhibit cell proliferation by arresting cells in mitotic prometaphase/metaphase^[1]. Mechanistically, maytansine, DM1 metabolites, and antibody-maytansinoid conjugates suppress microtubule dynamic instability rather than requiring microtubule depolymerization at active concentrations^[1][2]. This antimitotic mechanism supports their use as cytotoxic payloads in antibody-drug conjugates, where monoclonal antibodies deliver maytansinoids to antigen-expressing tumor cells^[3]. In breast tumor cells, anti-EpCAM-DM1 conjugates required internalization and intracellular processing before inducing abnormal spindle organization and mitotic arrest^[1]. In mouse xenograft models, T-DM1, SAR3419, and IMGN901 delivered active maytansinoid catabolites to tumor tissue, and linker chemistry affected plasma pharmacokinetics and catabolites in tumor and liver tissues^[4]. Compared with colchicine-site agents, maytansinoids act at the vinblastine-maytansine tubulin-binding site, defining a mechanistic distinction among antimitotic tubulin ligands^[5]. For research applications, DM1 and DM4 conjugates provide tools to study target-dependent cytotoxicity, linker-dependent ADME, microtubule dynamics, mitotic arrest, and ADC activity in tumor models^[1][3][4].